✦ LIBER ✦

Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma

✍ Scribed by Mirjam J. A. Engelen; Henrike E. Kos; Pax H. B. Willemse; Jan G. Aalders; Elisabeth G. E. de Vries; Michael Schaapveld; Renee Otter; Ate G. J. van der Zee

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 129 KB
Volume: 106
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21616

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Neoadjuvant chemotherapy followed by tum

Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma

✍ Walther Kuhn; Stefan Rutke; Kerstin Späthe; Barbara Schmalfeldt; Gerd Florack; B 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 1 views

Long-term disease-free survival effected

Long-term disease-free survival effected by gemcitabine in a heavily pretreated patient with recurrent ovarian carcinoma

✍ Benjamin Piura 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 56 KB

Tumor infiltration by FcγRIII (CD16)+ my

Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma

✍ Giuseppe Sconocchia; Inti Zlobec; Alessandro Lugli; Diego Calabrese; Giandomenic 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 458 KB

## Abstract The prognostic significance of macrophage and natural killer (NK) cell infiltration in colorectal carcinoma (CRC) microenvironment is unclear. We investigated the CRC innate inflammatory infiltrate in over 1,600 CRC using two independent tissue microarrays and immunohistochemistry. Surv

Level of anti-mouse-antibody response in

Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival

✍ Silvia Miotti; Donatella R.M. Negri; Olga Valota; Marcella Calabrese; Reinder L. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 88 KB

More than 60% of cancer patients injected with intact murine monoclonal antibody (MAb) develop a humoral response against the antigen even after a single dose. Analysis of a series of 35 ovarian-cancer patients entered in phase-I and -II clinical studies of T-cells retargeted with the bi-specific F(